Clinical Scorecard: Overall Survival in Black Patients Newly Diagnosed With Multiple Myeloma During the Triplet and Quadruplet Therapy Era
At a Glance
Category
Detail
Condition
Newly diagnosed multiple myeloma (MM)
Key Mechanisms
The study examined overall survival by race in relation to clinical characteristics, treatment access, triplet or quadruplet therapy, and stem cell transplantation; it did not investigate disease mechanisms.
Target Population
Adults aged 18 years or older with newly diagnosed, histologically confirmed active MM at Cleveland Clinic from January 1, 2017, through December 31, 2023.
Care Setting
Retrospective cohort at an integrated health system, including Taussig Cancer Center and regional hospitals in Ohio and Florida.
Key Highlights
The cohort included 1,209 patients; 22.7% were Black and 74.2% were White.
Within one year of diagnosis, 58.2% of Black patients and 55.9% of White patients received triplet or quadruplet therapy.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Overall survival was determined using the electronic health record and linked state and federal death records. Follow-up was censored at the earliest of April 30, 2026, five years after diagnosis, or the end of EHR follow-up availability.
Risks
Patient & Prescribing Data
Adults with newly diagnosed MM treated at Cleveland Clinic from 2017 through 2023; mean age was 67.3 years, and 54.1% were male.
Overall, 56.7% received triplet or quadruplet therapy within one year of diagnosis. Use was 58.2% among Black patients and 55.9% among White patients. The article reports lower stem cell transplant receipt among Black patients but the supplied text does not quantify the difference.
Clinical Best Practices
Interpret findings in the context of the study’s retrospective design and single integrated health-system setting.
The study assessed treatment patterns and survival; the supplied text does not establish that treatment patterns caused any observed outcomes.
